Talquetamab and Teclistamab: A Powerful Duo for Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
The combination of talquetamab and teclistamab has shown remarkable efficacy in treating patients with relapsed/refractory multiple myeloma (R/R MM) and extramedullary disease (EMD), according to updated results from the RedirecTT-1 study. This phase 2 trial, led by Dr. Saad Usmani from Memorial Sloan Kettering Cancer Center, New York, revealed that this innovative therapy can provide deep and durable responses for patients with triple-class exposed (TCE) R/R MM and EMD.
Key Findings:
- Efficacy: The overall response rate (ORR) was an impressive 77.8%, with 50% of patients achieving a complete response (CR) or better. The 12-month duration of response (DOR) was 60.1%, and progression-free survival (PFS) was 55.6%. Overall survival (OS) was 73.8%.
- Tumor Response: Response rates were significantly higher in patients with smaller EMD tumor volumes (<25 cm²), reaching 90.7% ORR and ≥60.5% CR. As tumor burden increased, response rates decreased.
- Safety: The combination therapy was well-tolerated, with no grade 3 or higher cytokine release syndrome (CRS) reported. Only 12.2% of patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS), and most adverse events were mild to moderate, including taste changes (79%), skin events (69%), and nail changes (56%).
A Controversial Takeaway
While the study's findings are promising, it's important to note that the research highlights the limitations of cross-study comparisons. Dr. Usmani and his team emphasize that further research is needed to understand the long-term efficacy and potential side effects of this combination therapy compared to other approved treatments.
A Thought-Provoking Question
As we delve into the world of precision medicine, how can we ensure that treatments like talquetamab and teclistamab are accessible and equitable for all patients with R/R MM and EMD? The discussion on treatment accessibility and patient outcomes is a crucial one, and we invite you to share your thoughts in the comments.
Source: Usmani S, et al. (2025). Efficacy and safety of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the RedirecTT-1 study with extended follow-up. Abstract 698, presented at the 2025 American Society of Hematology (ASH) Annual Meeting & Exposition.
